Ransh Pharma Profile
Key Indicators
- Authorised Capital ₹ 11.00 Cr
as on 21-12-2024
- Paid Up Capital ₹ 10.90 Cr
as on 21-12-2024
- Company Age 6 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 19.75 Cr
as on 21-12-2024
- Revenue 298.34%
(FY 2023)
- Profit 100.22%
(FY 2023)
- Ebitda 297.35%
(FY 2023)
- Net Worth 0.13%
(FY 2023)
- Total Assets 23.96%
(FY 2023)
About Ransh Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 11.00 Cr and a paid-up capital of Rs 10.90 Cr.
The company currently has active open charges totaling ₹19.75 Cr.
Gowri Rao, Karri Rao, Narasingarao Karri, and Four other members serve as directors at the Company.
- CIN/LLPIN
U74994AP2018PTC108036
- Company No.
108036
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Mar 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Visakhapatnam, Andhra Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Ransh Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chitakana Rao  | Managing Director | 19-Feb-2022 | Current |
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Gowri Rao | Director | 28-Mar-2018 | Current |
| Karri Rao | Director | 13-Jun-2018 | Current |
| Narasingarao Karri | Director | 13-Jun-2018 | Current |
| Vijaya Villuri | Director | 19-Feb-2022 | Current |
| Naidu Kandregula | Director | 19-Feb-2022 | Current |
| Venkata Putta | Director | 19-Feb-2022 | Current |
Financial Performance of Ransh Pharma.
Ransh Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 298.34% increase. The company also saw a substantial improvement in profitability, with a 100.22% increase in profit. The company's net worth moved up by a moderate rise of 0.13%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ransh Pharma?
In 2023, Ransh Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Sidbi Creation Date: 12 Oct 2023 | ₹3.90 Cr | Open |
Others Creation Date: 29 Apr 2023 | ₹1.77 M | Open |
Sidbi Creation Date: 07 Feb 2022 | ₹2.18 Cr | Open |
How Many Employees Work at Ransh Pharma?
Ransh Pharma has a workforce of 0 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ransh Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ransh Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
